Alder Biopharmaceuticals, Inc. (ALDR) Analysts See $-1.16 EPS

July 14, 2018 - By Mary Gaskins

Analysts expect Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) to report $-1.16 EPS on August, 14.They anticipate $0.32 EPS change or 21.62 % from last quarter’s $-1.48 EPS. After having $-1.73 EPS previously, Alder Biopharmaceuticals, Inc.’s analysts see -32.95 % EPS growth. The stock increased 3.77% or $0.7 during the last trading session, reaching $19.25. About 774,093 shares traded. Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has declined 8.80% since July 14, 2017 and is downtrending. It has underperformed by 21.37% the S&P500.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Coverage

Among 4 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Alder Biopharmaceuticals had 5 analyst reports since January 30, 2018 according to SRatingsIntel. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has “Buy” rating given on Thursday, February 8 by Canaccord Genuity. The rating was maintained by Canaccord Genuity on Tuesday, January 30 with “Buy”. BMO Capital Markets maintained the stock with “Outperform” rating in Wednesday, May 9 report. The company was reinitiated on Wednesday, June 27 by Needham.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The company has market cap of $1.31 billion. The company's lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It currently has negative earnings. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis.

More news for Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) were recently published by: Fool.com, which released: “Here’s Why Alder Biopharmaceuticals Is Rising Today” on June 15, 2018. Globenewswire.com‘s article titled: “Report: Developing Opportunities within Newfield Exploration, Heritage Insurance, AptarGroup, Alder …” and published on June 29, 2018 is yet another important article.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.